We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+26.72%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$6.52B
AUM Growth
+$1.41B
Cap. Flow
+$327M
Cap. Flow %
5.01%
Top 10 Hldgs %
29.27%
Holding
172
New
29
Increased
68
Reduced
18
Closed
14

Top Buys

Rank Stock Value
1
PRAX icon
Praxis Precision Medicines
PRAX
+$137M
2
VITL icon
Vital Farms
VITL
+$64.9M
3
YETI icon
Yeti Holdings
YETI
+$40.8M
4
GTM
ZoomInfo Technologies
GTM
+$36.8M
5
CWEN icon
Clearway Energy Class C
CWEN
+$32.9M

Top Sells

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$84.7M
2
IPHI
INPHI CORPORATION
IPHI
+$51M
3
W icon
Wayfair
W
+$46.2M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$37.1M
5
RCKT icon
Rocket Pharmaceuticals
RCKT
+$35.4M

Sector Composition

Rank Sector Weight
1 Healthcare 42.34%
2 Technology 25.33%
3 Industrials 10.16%
4 Consumer Discretionary 6.65%
5 Communication Services 4.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALLK
51
DELISTED
Allakos
ALLK
$44.4M 0.68%
317,000
+157,000
+98% +$16.3M
FRLN
52
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
$44.3M 0.68%
165,710
+9,490
+6% +$2.39M
CCI icon
53
Crown Castle
CCI
$33.4B
$44.2M 0.68%
277,400
+6,100
+2% +$989K
SNDX icon
54
Syndax Pharmaceuticals
SNDX
$1.73B
$43.3M 0.66%
1,946,000
+1,246,800
+178% +$25.9M
ZNTL icon
55
Zentalis Pharmaceuticals
ZNTL
$350M
$43.2M 0.66%
832,000
-79,416
-9% -$3.58M
IMVT icon
56
Immunovant
IMVT
$8.11B
$43M 0.66%
932,000
– –
EIDX
57
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$41.8M 0.64%
317,417
– –
CWEN icon
58
Clearway Energy Class C
CWEN
$4.94B
$39.8M 0.61%
1,247,300
+1,097,200
+731% +$32.9M
EDIT icon
59
PUT
Editas Medicine
EDIT
$413M
$38M 0.58%
+583,900
New +$24M
KURA icon
60
Kura Oncology
KURA
$826M
$34.6M 0.53%
1,060,000
+660,000
+165% +$23.2M
NRIX icon
61
Nurix Therapeutics
NRIX
$2.45B
$34.5M 0.53%
1,050,000
+552,260
+111% +$18.3M
ADCT icon
62
ADC Therapeutics
ADCT
$141M
$34.4M 0.53%
1,075,000
+494,517
+85% +$16.2M
NBIX icon
63
Neurocrine Biosciences
NBIX
$18.7B
$33.8M 0.52%
353,000
-7,200
-2% -$695K
NOVT icon
64
Novanta
NOVT
$4.95B
$33.1M 0.51%
280,000
-2,492
-0.9% -$291K
GNRC icon
65
Generac Holdings
GNRC
$11.3B
$32.5M 0.5%
+143,000
New +$30.8M
CLDX icon
66
Celldex Therapeutics
CLDX
$3.02B
$32.2M 0.49%
1,837,108
+1,330,929
+263% +$24M
MDB icon
67
MongoDB
MDB
$26.2B
$31.9M 0.49%
88,980
+1,183
+1% +$330K
KALV
68
DELISTED
KalVista Pharmaceuticals
KALV
$31.9M 0.49%
1,680,000
– –
NTLA icon
69
PUT
Intellia Therapeutics
NTLA
$1.55B
$30.3M 0.47%
+551,400
New +$20M
SMAR
70
DELISTED
Smartsheet Inc.
SMAR
$30.3M 0.46%
437,000
– –
CGNX icon
71
Cognex
CGNX
$10.4B
$28.8M 0.44%
359,000
– –
MRTX
72
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$28.4M 0.44%
129,471
-171,529
-57% -$37.1M
ROL icon
73
Rollins
ROL
$18.5B
$28.4M 0.44%
727,500
– –
SWKS icon
74
Skyworks Solutions
SWKS
$9.4B
$27.6M 0.42%
180,547
+22,570
+14% +$3.3M
OKTA icon
75
Okta
OKTA
$24.4B
$27.5M 0.42%
108,000
– –
1 2
3
4 5

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q4 2020 Portfolio in Review

As of Q4 2020, Eventide Asset Management held 172 positions worth $6.52B, up 28% from $5.11B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Eventide Asset Management deployed $327M of net new capital in Q4 2020, opening 29 new positions and adding to 68 existing holdings. Its largest new stake was Praxis Precision Medicines: 234,205 shares worth $184M.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 41% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Wayfair, an estimated $46.2M trimmed.

  • Eventide Asset Management's largest Q4 2020 buy was Praxis Precision Medicines: 234,205 shares worth $184M.
  • Eventide Asset Management added most to ZoomInfo Technologies in Q4 2020, an estimated $36.8M increase.
  • Eventide Asset Management's biggest Q4 2020 reduction was Wayfair, cutting an estimated $46.2M.
  • Eventide Asset Management fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $84.7M.
  • Eventide Asset Management's ten largest holdings make up 29% of its $6.52B portfolio in Q4 2020.
  • Eventide Asset Management opened 29 new positions and closed 14 in Q4 2020.
  • Eventide Asset Management's portfolio value rose 28% quarter-over-quarter to $6.52B.

Based on Eventide Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.